Literature DB >> 2569318

Different affinities of alpha 2-agonists for imidazoline and alpha 2-adrenergic receptors.

I Coupry1, V Lachaud, R A Podevin, E Koenig, A Parini.   

Abstract

It has recently been shown that imidazoline alpha 2-adrenergic agonists, such as clonidine and UK 14,304, selectively bind to both alpha 2- and imidazoline receptors in basolateral membranes from rabbit renal proximal tubule. In order to define the relative affinity of three antihypertensive alpha 2-agonists for the two classes of receptors, we performed competition studies of imidazoline alpha 2-antagonist 3H-RX 781094 and nonimidazoline antagonist 3H-rauwolscine binding to basolateral membranes from rabbit proximal tubule. The order of potency for inhibition of radioligand binding to basolateral membranes was rilmenidine greater than clonidine greater than guanfacine and clonidine greater than guanfacine greater than rilmenidine for 3H-RX 781094 and 3H-rauwolscine binding, respectively. These data show that not only clonidine, but also rilmenidine and guanfacine, drugs usually used as specific alpha 2-agonists, bind to both alpha 2- and imidazoline receptors. The higher affinity of these molecules for one or the other class of receptors could explain their different capacity to induce hypotension and side effects.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2569318     DOI: 10.1093/ajh/2.6.468

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  5 in total

1.  Modulation of L-DOPA's antiparkinsonian and dyskinetic effects by α2-noradrenergic receptors within the locus coeruleus.

Authors:  Corinne Y Ostock; Joy Hallmark; Noel Palumbo; Nirmal Bhide; Melissa Conti; Jessica A George; Christopher Bishop
Journal:  Neuropharmacology       Date:  2015-03-25       Impact factor: 5.250

2.  The Emerging Neurobiology of Attention Deficit Hyperactivity Disorder: The Key Role of the Prefrontal Association Cortex.

Authors:  Amy F T Arnsten
Journal:  J Pediatr       Date:  2009-05-01       Impact factor: 4.406

3.  Dose-effect relationship of rilmenidine after chronic administration.

Authors:  R Luccioni; M Lambert; P Ambrosi; M Scemama
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

4.  Alpha 2A adrenergic receptor agonist, guanfacine, attenuates cocaine-related impairments of inhibitory response control and working memory in animal models.

Authors:  Alvin V Terry; Patrick M Callahan; Rosann Schade; Nancy J Kille; Marc Plagenhoef
Journal:  Pharmacol Biochem Behav       Date:  2014-09-19       Impact factor: 3.533

5.  Once-daily treatment of ADHD with guanfacine: patient implications.

Authors:  Brandon C Strange
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.